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1058-73 Microsimulation to Support Prosthetic Aortic Valve 
Selection
Johanna J.M. Takkenberg, John P.A. Puvimanasinghe, Marinus J.C. Eijkemans, Lex A. 
van Herwerden, Ewout W. Steyerberg, J. Dik F. Habbema, Ad J.J.C. Bogers, Erasmus 
MC, Rotterdam, The Netherlands
Background. Prognosis after aortic valve replacement (AVR) is determined by multiple
inter-related factors, and objective selection of the preferred valve substitute can be diffi-
cult. Standard statistical methods do not allow detailed insight into the factors that affect
outcome in the individual patient.
Methods. The use of a microsimulation state-transition model to predict age- and gender-
specific outcome is illustrated using meta-analyses on the occurrence of valve-related
events and outcome after AVR with different valve substitutes (bileaflet mechanical
valves (N=2986), stented bioprostheses (N=5837), allografts (N=629) and autografts
(N=380)). The microsimulation model uses the meta-analysis information to generate a
large number (10,000) of age and gender-specific life histories of patients after AVR,
allowing detailed insight into all probable outcomes after AVR for patients with this spe-
cific age and gender. The impact of valve-related events, excess mortality due to heart
valve disease, and other non-valve-related events on survival can thus be quantified.
Results. Compared to healthy age-matched people, life expectancy of patients after AVR
is markedly reduced, especially at a younger age. For a 40-year-old male patient mean
life expectancy after AVR is reduced from 35 to 19-20 years, depending on the type of
prosthesis used. This reduction is mainly due to excess mortality (14 years), while valve-
related events play a minor role (1-2 years). Reoperation for structural valve deterioration
is common in younger patients with tissue valves, causing 4-5% of all deaths for patients
aged 40, depending on the type of tissue valve. On the other hand, younger patients with
mechanical valves have a high lifetime risk of suffering thrombo-embolic and bleeding
events, causing for example 4% of mortality in patients aged 40 years.
Conclusion. Microsimulation allows detailed insight into the factors that affect outcome
after AVR. Valve-related events play a minor but important role, since their effect on life
expectancy can be minimized by choosing the ‘best’ valve substitute for the individual
patient. In this respect microsimulation is a useful and objective decision support tool.
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1077-67 Guideline-Based Standardized Care Substantially 
Reduces Mortality in Medicare Patients With Acute 
Myocardial Infarction: The American College of 
Cardiology’s Guidelines Applied in Practice Program in 
Michigan
Kim A. Eagle, Cecelia K. Montoye, Arthur L. Riba, Anthony C. DeFranco, Robert Parrish, 
Stephen Skorcz, Patricia L. Baker, Benrong Chen, Canopy Roychoudhury, Rajendra H. 
Mehta, University of Michigan, Ann Arbor, MI
Background: It has been shown that the American College of Cardiology (ACC) Guide-
lines Applied in Practice (GAP) program improves adherence to key evidenced-based
therapies in acute myocardial infarction (AMI), particularly when standardized care tools
are used. To assess the impact of GAP on mortality, we studied 30-day and 1-year (yr)
mortality in 2857 Medicare Beneficiaries cared for at 33 hospitals in Michigan during the
3 GAP projects.
Methods: We compared baseline features, in-hospital treatments, and outcomes in 1368
patients cared for prior to GAP and 1489 patients treated after GAP. Logistic regression
models were built to identify clinical variables predictive of 30 day and 1-yr mortality. We
tested effects of the GAP project and the use of standard orders and discharge tool on
mortality.
Results: Pre and post GAP patients were similar in demographics, clinical presentation,
co-morbidities and complications. Multivariate predictors of mortality were old age, heart
failure, increased heart rate, chest pain, atrial fib, MI location, anemia, LVEF, troponin
level, and PCI /CABG: 0.76 C-statistic. Both GAP and use of standardized care tools
were associated with significantly lower 30 day and 1-yr mortality.
Conclusions: The ACC AMI GAP program is associated with a reduced 30-day and 1-yr
mortality among Medicare Beneficiaries. This independent and substantial mortality
reduction is realized in patients who receive system-based care with standard, guideline-
based orders and/or discharge tools. 
1077-68 Decreasing Mortality in Primary Percutaneous Coronary 
Intervention in Northern New England Is Related to 
Efforts at Regional Quality Improvement
Theodore Silver, Mirle Kellett, Jr., Winthrop Piper, Michael Hearne, Peter VerLee, 
Thomas Wharton, John Robb, Matthew Watkins, David Malenka, for the Northern New 
England Cardiovascular Disease Study Group, Dartmouth-Hitchcock Medical Center, 
Lebanon, NH
Background: Primary PCI has become the treatment of choice for STEMI and a focus of
quality improvement efforts (e.g., early recognition, decreased door-to-balloon time) in
Northern New England hospitals. We hypothesized that these efforts would be temporally
associated with lower inhospital mortality for this patient population.
Methods: We studied 3,013 consecutive cases of primary PCI contributed by 8 hospitals
to the Northern New England PCI Registry from 1994 to 2001 to assess changes in
case-mix and inhospital mortality.
Results: Over the study period annual caseload increased from 165 to 535 (Figure).
Case-mix remained stable over time. Crude mortality declined significantly from 6.1% to
3.2% (ptrend=0.01), as did adjusted mortality (ptrend<0.01), and was observed at all
institutions. The declining mortality was seen across patient subsets including those over
age 70 (ptrend=0.02), women (ptrend=0.08), those with left main disease (ptrend=0.01),
and in patients with multivessel disease (p=0.10).
Conclusion: Since 1994 regional mortality associated with primary PCI has decreased
by 48%. While likely multifactorial, it was clearly concurrent with regional efforts at quality
improvement.
1077-69 Underutilization of Effective Treatement in Diabetic 
Patients Admitted With Acute Myocardial Infarction
Dennis T. Ko, Alice M. Newman, Douglas S. Lee, Peter C. Austin, Linda R. Donovan, Jack 
V. Tu, Sunnybrook and Women's College Health Sciences Center, Toronto, ON, Canada, 
Institute for Clinical Evaluative Sciences, Toronto, ON, Canada
Background
Diabetic patients suffering acute myocardial infarction (AMI) have significantly higher
mortality compared with non-diabetic patients. While it has been demonstrated that
thrombolytics are underused in diabetic patients, it is unclear whether other effective
therapies are also underutilized.
Methods 
We analyzed the Enhanced Feedback for Effective Cardiac Treatment (EFFECT) data-
base, an initiative to improve care that collected information for patients admitted with an
AMI in Ontario, Canada during 1999 to 2001.
Results
There were 7,207 AMI patients, 25% had diabetes and 75% did not. Diabetic AMI
patients were significantly older (71 vs 68 years), more likely to be female (41% vs 34%),
had higher likelihood of comorbid conditions, and had higher adjusted mortality at 30-
days (14% vs 11%). Among ideal candidates, aspirin and beta blockers were prescribed
less often both on admission and at discharge in diabetics. However, ACE inhibitors were
prescribed more often compared with non-diabetics at discharge. (Table)
Conclusions
Despite higher risk of death, life-saving therapies such as aspirin and beta blockers are
substantially underutilized in diabetic patients with AMI. Improving the quality of care in
In-hospital, 30 day and 1-year Mortality Rates
GAP No 
GAP
p 
value
Odds Ratio Care 
Tools
No 
Tools
p value Odds Ratio
In 
hospital
10.7% 13.6% 0.017 ------- 8.7% 13.1% 0.0009 ------
30 day 16.7% 21.6% 0.001 1.35 (CI 1.07-1.70) 13.6% 22.4% <0.0001 1.73 (CI 1.27-2.35)
1 year 33.2% 38.3% 0.004 1.28 (CI 1.06-1.56) 29.3% 40.7% <0.0001 1.39 (CI 1.08-1.80)
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these patients with poor long-term outcome may represent a significantly opportunity to
improve their prognosis.
Table. 
*Adjusted for age, sex, hospital characteristics.
1077-70 Implementation of Acute Myocardial Infarction 
Guidelines in Community Hospitals Without Cardiac 
Catheterization Labs: Are We There Yet?
David M. Larson, Scott W. Sharkey, Barbara T. Unger, Timothy D. Henry, Minneapolis 
Heart Institute Foundation, Minneapolis, MN, Ridgeview Medical Center, Waconia, MN
Background
In order to reduce delays to treatment for ST Elevation Myocardial Infarction (STEMI), the
National Heart Attack Alert Program, in 1993, recommended that emergency depart-
ments (ED) develop protocols for STEMI and monitor quality measures including time to
treatment intervals. The ACC/AHA guidelines on STEMI recommend specific protocols to
rapidly assess and treat STEMI patients. The goal of this study was to obtain information
regarding the current use of STEMI protocols, adherence to guidelines and quality
assessment practices in hospitals without catheterization labs in Minnesota.
Methods
In March 2003, we mailed surveys to ED medical directors or nurse managers in 111
Minnesota hospitals that did not have cardiac catheterization labs. In addition to hospital
size and distance to nearest cath lab, the survey asked the questions regarding proto-
cols, standing orders, quality assurance, decision making and indications for transfer of
pts with STEMI. 
Results
103 (93%) of hospitals surveyed responded (10 to 173 beds; mean 42) located from 12
to 300 miles (mean 74) from the nearest cardiac cath lab. Only 64% of hospitals had
STEMI protocol/guidelines and 45% had standing orders in the ED; 32% had neither. Of
those hospitals that had specific guidelines, only 6% addressed criteria for transfer to a
tertiary hospital. Decisions addressed in guidelines: indications and dose of thrombolyt-
ics (58%), indications and dose of beta blockers (48%), use of aspirin (62%), indications
and dose of heparin (54%), and low molecular weight heparin (23%). Only 50% of hospi-
tals have a formal Quality assessment process for STEMI. Door to drug intervals are
monitored in 53% of hospitals; use of aspirin in 46% and beta blockers in 35%.
Conclusion
Despite recommendations from the NHAAP and ACC/AHA to develop hospital specific
guidelines and protocols for STEMI, only two thirds of community hospitals in Minnesota
have these in place. These guidelines are incomplete and rarely address transfer criteria
to hospitals with PCI capability. Quality performance measurement was lacking in one
half of hospitals surveyed. Programs to help community hospitals develop and implement
guidelines should be encouraged.
1077-71 The Association Between Care and Outcomes in 
Patients With Acute Coronary Syndrome: National 
Results From CRUSADE
Eric D. Peterson, Matthew T. Roe, Barbara L. Lytle, L. Kristin Newby, Elizabeth S. Fraulo, 
W. Brian Gibler, E. Magnus Ohman, Duke Clinical Research Institute, Durham, NC, 
University of North Carolina at Chapel Hill, Chapel Hill, NC
Background: Demonstrating the association between adherence to ACC/AHA guide-
lines and better outcomes is an important step in motivating their adoption in clinical
practice. Methods: Using data from the CRUSADE Initiative, we studied 45,987 high-risk
ACS patients (ischemic ST changes and/or positive cardiac markers) treated at 403 US
hospitals between 4/00-4/03. We evaluated hospitals’ use of 9 ACC/AHA Class I care
indicators among eligible patients without contraindications. Hospitals were divided into
quartiles based on overall guidelines adherence, calculated as % of guidelines consistent
care out of total care opportunities. Results: There were significant performance gaps
for each of the 9 indicators between the leading and lagging hospital quartiles: from nar-
row (97 vs 88% for aspirin <24 hrs, p<0.0001) to wide (60 vs 28%, p<0.0001 for GP IIb-
IIIa inhibitors <24 hrs). Compared with lagging, leading centers tended to be larger
(mean bedsize 388 vs 321), more likely academic (34 vs 21%), and to have CABG/PCI
facilities (81 vs 59%, all p<0.001). The Figure displays average in-hospital mortality for
each hospital performance quartile after adjusting for patient and hospital features. Con-
clusion: Adherence to ACC/AHA Guidelines varies markedly among US hospitals. Hos-
pitals with the highest adherence have significantly better patient outcomes than those
less adherent. These data support the need for national ACS quality improvement efforts
designed to promote local change. 
1077-72 Assessment of Glycemic Control in Patients With 
Diabetes Mellitus Admitted With an Acute Coronary 
Syndrome
Darcy Green Conaway, David M. Safley, Philip G. Jones, Jonathan Enriquez, Michelle 
Stephan, John A. Spertus, Mid-America Heart Institute, Kansas City, MO, University of 
Missouri, Kansas City, MO
BACKGROUND:No diabetic patient should be treated for an acute coronary syndrome
(ACS) without also directing attention to their diabetes and its associated metabolic
abnormalities. To understand whether physicians are also attending to patients diabetes
at the time of their ACS, we describe the proportion of diabetic patients who have their
glycemic control assessed during an ACS hospitalization .
METHODS: 968 consecutive patients were prospectively determined to have an ACS.
Prospective chart review and retrospective analyses of laboratory data were performed
to determine whether ACS patients with known diabetes had a glycosylated hemoglobin
(HbA1c) assessed 90 days prior to or during their hospitalization. We also examined
whether patient characteristics or processes of care were associated with HbA1c assess-
ments.
RESULTS: Among diabetic ACS patients (n=235, 24%), HbA1c values were obtained in
163 (69%). Older patients were less likely than younger patients to have had an HbA1c
checked (60% of patients >/=70 vs. 67% for ages 60-69 vs. 79% for ages <60, p=0.02).
Of the 235 diabetic patients, 89 had an endocrinology consultation. Of the 59 patients
who received an endocrine consult without a prior HbA1c, 54 (92%) had one checked
after the consult. Of the 146 patients not receiving an endocrine consult, HbA1c values
were checked in 79 (54%, p<0.001 compared to those who had a consult). The admitting
blood sugars of patients without a consult or HgA1c were elevated (161±60 mg/dL; >200
mg/dL in 25% of patients).
CONCLUSIONS: Almost a third of known diabetics have no recent evaluation of their gly-
cemic control prior to or during an ACS admission. Older age and no endocrinology con-
sultation are associated with less frequent assessments of HbA1c. These data suggest
an important opportunity to improve diabetes care at the time of an ACS.
1077-73 Enhancing Quality of Heart Failure Care in Managed 
Medicare and Medicaid in North Carolina: Results of the 
North Carolina Achieving Cardiac Excellence (NC ACE) 
Project
David C. Goff, Jr., Mark W. Massing, Alain G. Bertoni, Jennifer Davis, Walter T. 
Ambrosius, Jill McArdle, Vanessa Duren-Winfield, Carla A. Sueta, Janet B. Croft, Wake 
Forest University Health Sciences, Winston-Salem, NC, Medical Review of North 
Carolina, Cary, NC
Background: Utilization of angiotensin converting enzyme inhibitors (ACE-I) and beta-
adrenergic receptor blockers (BB) in heart failure (HF) patients remain suboptimal
despite the results of clinical trials and evidence-based guidelines supporting their
use.This report provides the results of a collaborative quality improvement program for
HF care implemented in managed Medicare and Medicaid programs in North Carolina.
Methods: Managed care plans identified adult patients with HF during 2000 (pre-inter-
vention) and from November 1, 2001 through October 31, 2002 (post-intervention). A
stratified random sample of patients’ outpatient medical records were reviewed by trained
nurse abstractors to obtain data regarding type of heart failure, demographics, comorbid-
ities, and therapies. The intervention consisted of guideline summary dissemination, per-
formance audit with feedback, patient-specific chart reminders and patient activation
mailings.
Results: We sampled 1613 patients from 5 plans during the pre-intervention period and
1528 patients during the post-intervention period. Assessment of left ventricular function
increased from 81.7% to 85.3% of patients (p < 0.0001). Among patients with moderate
to severe left ventricular systolic dysfunction, there was no substantive change in treat-
ment with ACE inhibitors or vasodilators; whereas, appropriate treatment with beta block-
ers increased from 48.3% (with another 11.9% with documented contraindications) to
67.9% (with another 7.5% with documented contraindications). The quality gap
decreased from 39.8% to 24.6% (p < 0.0001).
Conclusion: Left ventricular function assessment improved despite high pre-intervention
rates. Treatment rates with ACE-I and vasodilators remained high, but did not improve.
Treatment rates with BB improved substantially translating into a significant public health
benefit. Given published data regarding benefits of BB, one might expect 50 fewer deaths
Diabetic 
Patients
Non-
Diabetic 
Patients
Adjusted Odds Ratio Diabetic/
Non-Diabetic (95% CI)*
Medications at within 6 
hrs of Admission, (%)
Aspirin 69 78 0.71 (0.61, 0.84)
Beta Blockers 25 33 0.77 (0.64, 0.92)
Medications at Discharge 
, (%)
Aspirin 80 86 0.67 (0.57, 0.79)
Beta Blockers 75 80 0.79 (0.66, 0.94)
ACE inhibitors 75 69 1.34 (1.05, 1.71)
Statins 56 63 0.86 (0.63, 1.18)
